Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 21;14(1):184.
doi: 10.1038/s41408-024-01155-y.

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

Rakesh Popat  1 , Bradley Augustson  2 , Mercedes Gironella  3 , Cindy Lee  4 , Paul Cannell  5 , Nashita Patel  6 , Ravi S Kasinathan  7 , Rachel Rogers  7 , Mehreen Shaikh  6 , Amy Curry  8 , Fernando Carreño  7 , Sumita Roy-Ghanta  7 , Joanna Opalinska  7 , Hang Quach  9
Affiliations

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

Rakesh Popat et al. Blood Cancer J. .

Abstract

PubMed Disclaimer

Conflict of interest statement

RP is supported by the Biomedical Research Center of the National Institute for Health Research and University College London Hospitals and received speaker honorarium from AbbVie, GSK, Janssen Biotech, Inc., BMS and Pfizer, has participated in advisory boards for GSK and Janssen Biotech, Inc., and has received research funding from GSK and Pfizer. BA has sat on scientific advisory boards for Janssen-Cilag Pty Ltd. MG discloses no conflicts of interest. CL has participated in advisory boards for Janssen-Cilag, BMS, Antengene, Takeda, and Amgen. PC discloses no conflicts of interest. NP, RSK, RR, MS, AC, FC, SR-G, and JO are employees of GSK and hold stocks/shares in GSK. HQ has received research funding from GSK, BMS, Karyopharm, and Abbvie, has received speaker honorarium for Beigene, GSK, and Abbvie and has participated on advisory boards for BMS, Abbvie, GSK, Janssen Cilag, Pfizer, Antengene, Sanofi and Regeneron.

Figures

Fig. 1
Fig. 1. ORR.
ORR was defined as a PR or better and CRR was defined as a confirmed CR or better; patients with unknown or missing responses were treated as non-responders. Deep responses are indicated as ≥VGPR. CI confidence interval; CR complete response; CRR complete response rate; ORR overall response rate; PR partial response; s stringent; VGPR very good partial response. From Belantamab Mafodotin in Combination with Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Analysis of DREAMM-6 Trial Arm-A/#2010, presented by Rakesh Popat at the 2023 ASH Annual Meeting. Reproduced with permission.
See this image and copyright information in PMC

References

    1. Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128–38. - PMC - PubMed
    1. De Oca RM, Gupta I, Shelton C. Abstract 6711: Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma. Cancer Res. 2020;80:6711.
    1. Trudel S, McCurdy A, Louzada ML, Parkin S, White D, Chu MP, et al. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nat Med. 2024;30:543–51. - PMC - PubMed
    1. Trudel S, McCurdy A, Fu M, Sutherland HJ, Louzada ML, Chu MP, et al. Belantamab Mafodotin in combination with pomalidomide and dexamethasone demonstrates durable responses in triple class exposed/refractory multiple myeloma. Blood. 2022;140:7306–7.
    1. Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Migkou M, Theodorakakou F, et al. Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study. Am J Hematol. 2024;99:502–4. - PubMed

LinkOut - more resources